Key Insights

Highlights

Success Rate

84% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

8.2%

6 terminated out of 73 trials

Success Rate

83.8%

-2.8% vs benchmark

Late-Stage Pipeline

8%

6 trials in Phase 3/4

Results Transparency

32%

10 of 31 completed with results

Key Signals

10 with results84% success

Data Visualizations

Phase Distribution

47Total
Not Applicable (21)
Early P 1 (1)
P 1 (14)
P 2 (5)
P 3 (2)
P 4 (4)

Trial Status

Completed31
Recruiting14
Not Yet Recruiting11
Terminated6
Active Not Recruiting4
Unknown4

Trial Success Rate

83.8%

Benchmark: 86.6%

Based on 31 completed trials

Clinical Trials (73)

Showing 20 of 20 trials
NCT07748637Early Phase 1Not Yet RecruitingPrimary

A Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Relapsing/Refractory Multiple Sclerosis

NCT04777539CompletedPrimary

Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple Sclerosis

NCT06800144Not ApplicableCompletedPrimary

Effect of Music Therapy on Pain in People With Multiple Sclerosis

NCT06957145CompletedPrimary

Vista Protein Expression of Monocyte and T Cell Subsets in Multiple Sclerosis and Its Clinical Correlation

NCT06053749Active Not RecruitingPrimary

An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden

NCT07680738Not ApplicableCompletedPrimary

Transcranial Direct Current Stimulation for Fatigue, Mood, and Cognition in Multiple Sclerosis

NCT05359653Phase 1RecruitingPrimary

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

NCT07676266Phase 1Not Yet RecruitingPrimary

A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

NCT06869278Phase 1WithdrawnPrimary

A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases

NCT07640698Not ApplicableNot Yet RecruitingPrimary

TELESM-edu.Nursing: a Personalised Nursing Intervention for People With Multiple Sclerosis

NCT05000216Phase 2Terminated

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

NCT07636434Not ApplicableNot Yet Recruiting

My MS Toolkit: An Internet-Based Depression Self-Management Program for Adults Living With Multiple Sclerosis

NCT07444047RecruitingPrimary

MRI-Based Lesion Differentiation in Older Patients With Multiple Sclerosis

NCT07599189Not ApplicableNot Yet RecruitingPrimary

Essential Oils for Urinary Symptoms in Multiple Sclerosis Patients

NCT04926818Phase 3Active Not RecruitingPrimary

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

NCT07526493Phase 1RecruitingPrimary

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

NCT06157086Active Not RecruitingPrimary

Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France

NCT06860932Not ApplicableRecruitingPrimary

A Palliative Care Model Impact on Knowledge and Attitudes

NCT07523100Phase 1Not Yet RecruitingPrimary

A Study on the Safety and Tolerability of Universal STAR-T Cell Therapy for Multiple Sclerosis.

NCT07195110CompletedPrimary

Prevalence of Periodontitis in Egyptian Multiple Sclerosis Patients.

Scroll to load more

Research Network

Activity Timeline